- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07772232
Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia
Prospective Randomized Controlled Comparison of Holmium Laser Enucleation of the Prostate With Robotic Water Jet Ablation
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
This prospective, randomized controlled trial is designed to compare the safety, effectiveness, and long-term durability of Holmium Laser Enucleation of the Prostate (HoLEP) utilizing MOSES 2.0 technology with Robotic Water Jet Ablation (RWJA) performed using the Hydros Robotic System for the treatment of benign prostatic hyperplasia (BPH). The trial will enroll 100 men aged 50 to 80 years who present with moderate-to-severe lower urinary tract symptoms secondary to BPH and prostate volumes between 50 and 180 mL. Participants will be randomized in a 1:1 ratio to receive either HoLEP or RWJA and will be monitored for five years following treatment.
The primary objective is to compare objective measures of treatment efficacy and durability at 12 months, specifically changes in prostate volume, prostate-specific antigen (PSA) levels, urinary flow rate (Qmax), and post-void residual urine volume (PVR). Secondary objectives include assessment of perioperative outcomes, safety profiles, patient-reported urinary and sexual function, treatment durability, reintervention rates, and healthcare resource utilization. Outcomes will be measured using validated instruments, such as the International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD), and Incontinence Severity Index (ISI).
Although both procedures are established and FDA-approved therapies for BPH, direct comparative evidence is limited. This study seeks to address this evidence gap by generating high-quality comparative effectiveness data to inform clinical decision-making and patient counseling. The results may clarify the relative benefits and tradeoffs of each procedure, particularly in terms of symptom improvement, preservation of sexual function, durability of treatment response, and long-term healthcare utilization.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Hazem Elmansy, MD
- Puhelinnumero: 346-516-1481
- Sähköposti: hmelmansy@houstonmethodist.org
Tutki yhteystietojen varmuuskopiointi
- Nimi: Miguel Valdivia y Alvarado, MD
- Puhelinnumero: 346-356-3622
- Sähköposti: mvaldiviayalvarado@houstonmethodist.org
Opiskelupaikat
-
-
Texas
-
Houston, Texas, Yhdysvallat, 77030
- Houston Methodist
-
Ottaa yhteyttä:
- Hazem Elmansy, MD
- Puhelinnumero: 346-516-1481
- Sähköposti: hmelmansy@houstonmethodist.org
-
Ottaa yhteyttä:
- Miguel Valdivia y Alvarado, MD
- Puhelinnumero: 346-356-3622
- Sähköposti: mvaldiviayalvarado@houstonmethodist.org
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- Male, age 50-80 years
- International Prostate Symptom Score (IPSS) ≥ 12
- Prostate size (TRUS): 50-180 mL
- Diagnosis of LUTS due to BPH
- Uroflow Qmax ≤ 15 mL/sec
- Mentally capable, able to comply with study procedures, written informed consent provided
- Able to follow study instructions and complete all required visits
Exclusion Criteria:
- BMI ≥ 42
- History of prostate cancer
- Suspected or history of bladder cancer
- Active or untreated bladder stones at screening
- Indwelling catheter for more than 3 months before baseline
- Active urinary tract infection
- History of urethral stricture or bladder neck stenosis
- Damage to the external urethral sphincter
- Previous prostate surgery or lower urinary tract surgery
- Use of obligatory anticoagulants (if not stoppable) or known coagulopathy (except ASA 100 mg/d)
- Contraindications to general and spinal anesthesia
- Any condition that could interfere with study participation or outcomes, per investigator judgment
- Lacks legal or mental capacity to consent
- Simultaneous participation in another therapeutic urological trial
- Known or persistent abuse of medication, drugs, or alcohol
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: HoLEP with MOSES 2.0
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
|
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
|
|
Active Comparator: RWJA with Hydros Robotic System
Robotic-assisted waterjet ablation of the prostate using the Hydros Robotic System, performed per institutional standard of care.
|
Device - RWJA (Hydros Robotic System) / Aquablation therapy (often referred to by its commercial name, "Aquablation").
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in Prostate Volume
Aikaikkuna: Baseline and 12 months post-intervention
|
Measured via transrectal ultrasound (TRUS); change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Prostate-Specific Antigen (PSA)
Aikaikkuna: Baseline and 12 months post-intervention
|
Serum PSA level; change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Urinary Flow Rate (Qmax)
Aikaikkuna: Baseline and 12 months post-intervention
|
Peak urinary flow rate via uroflowmetry; change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Post-Void Residual Volume (PVR)
Aikaikkuna: Baseline and 12 months post-intervention
|
Bladder scan-measured PVR; change from baseline.
|
Baseline and 12 months post-intervention
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Incidence and Severity of Adverse Events
Aikaikkuna: From patient hospital discharge through 3 and 12 months post-surgery
|
Adverse events graded by the Clavien-Dindo classification system.
|
From patient hospital discharge through 3 and 12 months post-surgery
|
|
Operative Time
Aikaikkuna: Day (duration) of surgical procedure
|
Total procedure time, start to finish.
|
Day (duration) of surgical procedure
|
|
Hemostasis Time
Aikaikkuna: Day (duration) of surgical procedure
|
Time required to achieve hemostasis intraoperatively.
|
Day (duration) of surgical procedure
|
|
Perioperative Change in Hemoglobin
Aikaikkuna: Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
|
Hemoglobin level change from baseline to immediate postoperative measurement.
|
Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
|
|
Time to Catheter-Free Status
Aikaikkuna: From surgery day until catheter removal
|
Duration from end of surgery to catheter removal.
|
From surgery day until catheter removal
|
|
Length of Hospital Stay / Discharge Time
Aikaikkuna: Day of surgical procedure through hospital discharge
|
Time from surgery to hospital discharge.
|
Day of surgical procedure through hospital discharge
|
|
Change in IPSS/QoL Score
Aikaikkuna: Baseline, 3, 6, and 12 months post-surgery
|
International Prostate Symptom Score / Quality of Life index.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in SHIM Score
Aikaikkuna: Baseline, 3, 6, and 12 months post-surgery
|
Sexual Health Inventory for Men.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in MSHQ-EjD Score
Aikaikkuna: Baseline, 3, 6, and 12 months post-surgery
|
Male Sexual Health Questionnaire - Ejaculatory Dysfunction.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in Incontinence Outcomes
Aikaikkuna: Baseline, 3, 6, and 12 months post-surgery
|
Incontinence Severity Index (ISI) score and Cough Stress Test (CST) result.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Long-Term Durability of Functional Improvements
Aikaikkuna: 24, 36, 48, and 60 months post-intervention
|
Composite tracking of IPSS, Qmax, PVR, PSA, and prostate volume.
|
24, 36, 48, and 60 months post-intervention
|
|
Post-Operative Medication Use
Aikaikkuna: Through 60 months post-intervention
|
Number of prescriptions written and filled (initial fills and refills), e.g., alpha-blockers, 5-alpha reductase inhibitors.
|
Through 60 months post-intervention
|
|
Reintervention Rate
Aikaikkuna: Through 60 months post-intervention
|
Repeat procedures or additional therapies for BPH/LUTS.
|
Through 60 months post-intervention
|
|
Unplanned Healthcare Encounters
Aikaikkuna: Through 60 months post-intervention
|
Emergency visits, urgent care visits, and add-on clinic visits related to the procedure.
|
Through 60 months post-intervention
|
|
Incidence of Urethral Stricture Requiring Intervention
Aikaikkuna: Through 60 months post-intervention
|
New urethral stricture or bladder neck stenosis requiring treatment.
|
Through 60 months post-intervention
|
|
Unanticipated Advanced Diagnostics
Aikaikkuna: Through 60 months post-intervention
|
Unplanned MRI, cystoscopy, or prostate cancer biomarker testing.
|
Through 60 months post-intervention
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- Pro00041304
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .